nach oben

Reactions Weekly

Erschienen in:

01.06.2019 | Case report

Atezolizumab/ipilimumab/pembrolizumab

Haemophagocytic lymphohistiocytosis: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Noseda R, et al. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: Analysis of WHO global database of individual case safety reports. Journal for ImmunoTherapy of Cancer 7: 117, No. 1, 2019. Available from: URL: http://doi.org/10.1186/s40425-019-0598-9 -Switzerland

Titel: Atezolizumab/ipilimumab/pembrolizumab
Haemophagocytic lymphohistiocytosis: 2 case reports
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63608-8

Isavuconazole

Case report

Chemotherapy with highest risk of peripheral neuropathy

Clinical study

Increased stroke risk in elderly with neurotransmitter inhibitors

Clinical study

Perampanel

Case report

Erythromycin

Case report

Multiple drugs

Case report

Springer Medizin

Atezolizumab/ipilimumab/pembrolizumab

Haemophagocytic lymphohistiocytosis: 2 case reports

Excerpt

Weitere Artikel der Ausgabe 1/2019

Isavuconazole

Chemotherapy with highest risk of peripheral neuropathy

Increased stroke risk in elderly with neurotransmitter inhibitors

Perampanel

Erythromycin

Multiple drugs

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Isavuconazole

Chemotherapy with highest risk of peripheral neuropathy

Increased stroke risk in elderly with neurotransmitter inhibitors

Perampanel

Erythromycin

Multiple drugs